Cargando…
Estimating the Product Lifecycle Value of Trastuzumab Based on Registry Data in Sweden
BACKGROUND AND OBJECTIVE: Trastuzumab was introduced in Sweden in 2000 for treatment of HER2-positive metastatic breast cancer (MBC) and later expanded to early breast cancer (EBC). The potential value of this innovative therapy was explored in economic evaluations; however, the extent to which thes...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374791/ https://www.ncbi.nlm.nih.gov/pubmed/37422544 http://dx.doi.org/10.1007/s40261-023-01279-2 |